Ghent University Academic Bibliography

Advanced

Rituximab: modes of action, remaining dispute and future perspective

Abdulmunem Abulayha, Amin Bredan, Hesham El Enshasy and Ian Daniels (2014) FUTURE ONCOLOGY. 10(15). p.2481-2492
abstract
Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
rituximab, NON-HODGKINS-LYMPHOMA, CHRONIC LYMPHOCYTIC-LEUKEMIA, caspases, mechanism, cell death, apoptosis, ANTI-CD20 MONOCLONAL-ANTIBODY, B-CELL LYMPHOMA, FC-GAMMA-RIIIA, DRUG-INDUCED APOPTOSIS, FAS-INDUCED APOPTOSIS, IN-VIVO, SIGNALING PATHWAY, PHASE-I
journal title
FUTURE ONCOLOGY
Future Oncol.
volume
10
issue
15
pages
2481 - 2492
Web of Science type
Article
Web of Science id
000346652100018
JCR category
ONCOLOGY
JCR impact factor
2.477 (2014)
JCR rank
123/211 (2014)
JCR quartile
3 (2014)
ISSN
1479-6694
DOI
10.2217/fon.14.146
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
5930159
handle
http://hdl.handle.net/1854/LU-5930159
date created
2015-04-10 12:15:21
date last changed
2017-03-07 09:37:22
@article{5930159,
  abstract     = {Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.},
  author       = {Abulayha, Abdulmunem and Bredan, Amin and El Enshasy, Hesham and Daniels, Ian},
  issn         = {1479-6694},
  journal      = {FUTURE ONCOLOGY},
  keyword      = {rituximab,NON-HODGKINS-LYMPHOMA,CHRONIC LYMPHOCYTIC-LEUKEMIA,caspases,mechanism,cell death,apoptosis,ANTI-CD20 MONOCLONAL-ANTIBODY,B-CELL LYMPHOMA,FC-GAMMA-RIIIA,DRUG-INDUCED APOPTOSIS,FAS-INDUCED APOPTOSIS,IN-VIVO,SIGNALING PATHWAY,PHASE-I},
  language     = {eng},
  number       = {15},
  pages        = {2481--2492},
  title        = {Rituximab: modes of action, remaining dispute and future perspective},
  url          = {http://dx.doi.org/10.2217/fon.14.146},
  volume       = {10},
  year         = {2014},
}

Chicago
Abulayha, Abdulmunem, Amin Bredan, Hesham El Enshasy, and Ian Daniels. 2014. “Rituximab: Modes of Action, Remaining Dispute and Future Perspective.” Future Oncology 10 (15): 2481–2492.
APA
Abulayha, Abdulmunem, Bredan, A., El Enshasy, H., & Daniels, I. (2014). Rituximab: modes of action, remaining dispute and future perspective. FUTURE ONCOLOGY, 10(15), 2481–2492.
Vancouver
1.
Abulayha A, Bredan A, El Enshasy H, Daniels I. Rituximab: modes of action, remaining dispute and future perspective. FUTURE ONCOLOGY. 2014;10(15):2481–92.
MLA
Abulayha, Abdulmunem, Amin Bredan, Hesham El Enshasy, et al. “Rituximab: Modes of Action, Remaining Dispute and Future Perspective.” FUTURE ONCOLOGY 10.15 (2014): 2481–2492. Print.